Brad O'Connor Chief Executive Officer
Brad O’Connor has been Managing Director and Chief Executive Officer of Cogstate Limited since December 2005. Brad has responsibility for Cogstate’s overall strategic direction and day-to-day operations as well as development of expansion opportunities outside of the core clinical trials business.
Brad is also a director of Cogstate Inc. and Cogstate Sport Inc. Prior to taking the position of CEO at Cogstate, Brad joined Cogstate as Chief Financial Officer and Company Secretary in May 2004. Prior to that, Brad held senior positions at Spherion Group, Australian Wine Exchange and PricewaterhouseCoopers. Brad is a chartered accountant who holds a Bachelor of Business degree.
George Hunnewell Chief Operating Officer and President, Clinical Trials
George Hunnewell is an accomplished senior executive with more than 25 years of experience growing clinical research and healthcare technology businesses. He brings deep general management expertise including sales and marketing, operations, finance, and mergers and acquisitions.
As Chief Operating Officer and President of Cogstate’s Clinical Trials division, George is responsible for worldwide operations including Regulatory & Quality Assurance, Product Development, Human Resources, as well as full P&L responsibility for the Clinical Trials business.
George previously served as Corporate Vice President, Clinical Research Services for Parexel International Corporation, and he earned an AB in Mechanical Engineering from Harvard University and an MBA from MIT Sloan School of Management.
Frank Cheng President, Healthcare
Frank Cheng is a medical technology industry executive with general management experience with both established industry leaders and venture-backed companies.
As President of Cogstate’s Healthcare Business, Frank is responsible for all aspects of commercializing Cogstate technologies in the healthcare marketplace. For this role, Frank utilizes his deep experience in building and growing new businesses in key worldwide markets (United States, the European Union, Canada, China and Japan) through achieving regulatory clearance, reimbursement approval and commercialization build-up.
Frank most recently served as Senior Vice President, Worldwide Marketing & Business Development at cardiac robotic innovator Stereotaxis Inc., where he led the company’s marketing, business development, training, clinical research, operations, as well as Asia P&L. His previous experience includes general management roles at GE Healthcare and Roche Diagnostics. Frank holds a BBA in International Finance from Wuhan University in China and an MBA from Vanderbilt University.
Lammert Albers Chief Commercial Officer
Lammert Albers is a business development executive with more than 15 years experience in the Life Science and Healthcare industries, driving global commercial strategies for leading clinical research organizations from discovery through post-marketing clinical trials.
As Chief Commercial Officer at Cogstate, Lammert is responsible for driving growth and strategic relationships for Cogstate’s Clinical Trials business, leading marketing, proposals and business development functions globally.
Lammert comes to Cogstate from PRA Health Sciences, having served as Vice President of Global Business Development and Engagement Partner, where he lead cross-divisional commercial teams. Lammert also held the role of Vice President Global Business Development and Strategic Relationships at MDS Pharma Services (later Clearstone Central Laboratories), as well as commercial and scientific roles with Genaissance Pharmaceuticals, Anachem Ltd and AstraZeneca.
Paul Maruff Chief Scientific Officer
Professor Paul Maruff is one of the founders of Cogstate. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioral and cognitive dysfunction. Paul’s research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods to guide decision making in drug development and in clinical medicine.
He has worked extensively on method to identify subtle neurocognitive impairment, and to assess the efficacy of pharmacological treatment, in Alzheimer’s disease, mild cognitive impairment and the HIV dementia complex. He has extended this approach to identify cognitive dysfunction, and monitor treatment efficacy in psychiatric diseases such as schizophrenia, obsessive-compulsive disorder and depression in adults, and attention deficit disorder, developmental dyspraxia and substance abuse in children.
Paul remains an active researcher. He is appointed Professor at the Florey Institute for Neuroscience and Mental Health. He is currently clinical co-chair of the Australian Imaging Biomakers and Lifestyle (AIBL) study. Paul has published over 250 research articles in international peer-reviewed scientific journals, and has co-authored 10 book chapters.
Richard Gleeson Chief Technology Officer
With a 20-year career of building and deploying technologies for healthcare and life science industries, Richard Gleeson brings deep expertise in high-impact innovations for the collection, analysis, management and integration of clinical trial data. As Cogstate’s Chief Technology Officer, Richard is responsible for providing the vision and leadership for technology initiatives to simplify the measurement of cognition.
Prior to joining Cogstate, Rich served as Vice President, Global Solution Delivery at PAREXEL Informatics, where he was responsible for the pre-sales, deployment and operations of their Clinical Trial Management, Electronic Data Capture, MyTrials Portal, and Analytics and Integration Platform. Previously, Rich was Vice President at Doctor Evidence, a Health Economics and Outcomes Research company and served as Senior Business Strategy Consultant at Microsoft, working with large enterprise customers from top 25 life science companies.
Rich earned a BA in Physics from Cal Poly and an MBA from Temple University’s Fox School of Business.
Roger O'Sullivan General Counsel, Corporate Secretary and Chief Privacy Officer
Mr. O’Sullivan has extensive experience as legal counsel for the healthcare and life sciences industries, bringing broad, frontline experience establishing strategic alliances and structuring and negotiating complex commercial/corporate transactions.
As Cogstate’s General Counsel, Corporate Secretary (Cogstate Inc.) and Chief Privacy Officer, Mr. O’Sullivan serves as key legal advisor on all major business transactions. He also oversees regulatory compliance and the development and protection of the company’s intellectual property portfolio.
Prior to joining Cogstate, Mr. O’Sullivan was founder and managing member of a New York life sciences boutique where he counseled small to mid-size biopharmaceutical companies regarding formation and strategic development.
Claire Newstead-Sinclair Finance Director
Ms. Newstead-Sinclair was appointed to the position of Company Secretary in 2010, prior to which she worked as a Finance Manager for OAMPS Insurance Brokers, part of the Wesfarmers Group. Claire studied accounting at Monash University and was admitted as a member of the Institute of Chartered Accountants in April 2004.